Cerus (CERS) Stock News

Cerus Corporation (CERS) announced its management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida. The presentation is scheduled for Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. Investors and interested parties can access a live webcast of the presentation through the Events & Presentation section on Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will remain available on the company's Investor Relations website for 30 days following the event.

Cerus Corporation (CERS) will present clinical data for its INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan from May 31 to June 4, 2025. The presentations will highlight data on the system's applications for platelets, plasma, cryoprecipitated fibrinogen complex, and red blood cells.

Key presentations include positive results from the Phase 3 ReCePI study in red blood cells, INTERCEPT treated cold stored platelets, and effective inactivation of California encephalitis virus. The event features a Cerus-sponsored symposium focusing on INTERCEPT's impact on adverse events, platelet use, and inventory management in France, along with its safety in neonates.

Multiple oral and poster presentations will cover topics including cold-stored platelet concentrates, reduced hemoglobin use in cardiac surgery, and pathogen reduction effectiveness.

Cerus Corporation (CERS) has secured regulatory approvals from French ANSM and Swiss Swissmedic for its INT200, a next-generation LED-based illumination device for the INTERCEPT Blood System. The INT200 features significant improvements over its predecessor, including a vertical configuration that allows three devices to fit in the space of one INT100, touch screen navigation, improved tray design, intelligent scanning, and custom reporting. This follows the CE Mark authorization received in March. Both France and Switzerland have been using INTERCEPT Blood System for all platelet components since 2018 and 2011 respectively. Cerus plans to convert its EMEA INT100 installed base to INT200s over the next three years and aims to submit a PMA to the FDA during 2026.

Cerus Corporation (CERS) reported strong Q1 2025 financial results with total revenue of $48.9M, up 13% year-over-year. Product revenue reached $43.2M, also up 13%, while government contract revenue was $5.6M. The company's INTERCEPT Fibrinogen Complex (IFC) showed significant growth with Q1 revenue of $3.0M compared to $1.9M in the prior year. Notable achievements include receiving CE Mark for INT200, their next-generation LED-based illumination device, and submitting an updated CE Mark application for the INTERCEPT red blood cell system. The company reported a net loss of $7.7M ($0.04 per share), improved from $9.7M loss year-over-year. With $80.9M in cash and equivalents, Cerus maintains its 2025 product revenue guidance of $194-200M. North American revenue grew 22%, while EMEA declined 4% due to forex impact.

Cerus (CERS) has scheduled the release of its first quarter 2025 financial results for Thursday, May 1, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss financial performance and provide business updates.

Management will present detailed financial results and offer a general business overview and outlook during the call. A replay of the event will be accessible on Cerus' website until May 22, 2025.

Cerus (CERS) has received CE mark approval for its next-generation LED-based illumination device (INT200) for the INTERCEPT Blood System for platelets and plasma under the EU Medical Device Regulation (MDR). This approval enables Cerus to market the INT200 throughout the European Union and regions recognizing CE mark certification.

The INT200 represents a significant upgrade featuring enhanced physical design and new software interface while maintaining compatibility with existing processing sets. This approval completes the authorization of the INTERCEPT Blood System for both platelets and plasma within the EU MDR framework, following the 2023 CE mark approvals of INTERCEPT processing sets.

The CE mark represents the first regulatory approval for Cerus' next-generation illuminator, with additional regulatory submissions planned over coming years. The INT200 will serve as the foundation for geographic expansion and future growth of the INTERCEPT business.

Cerus (CERS) reported strong financial results for full-year and Q4 2024. Full-year product revenue reached $180.3 million, up 15% year-over-year, while Q4 product revenue was $50.8 million, a 9% increase. The company achieved significant financial improvements, including a 40% reduction in GAAP net loss to $20.9 million and positive non-GAAP adjusted EBITDA of $5.7 million for 2024.

Notable achievements include four consecutive quarters of positive operating cash flows, totaling $11.4 million for the year, a $55 million improvement from 2023. The INTERCEPT Fibrinogen Complex (IFC) product showed strong growth, with full-year revenue of $9.2 million, up 42% from the previous year.

The company reiterated its 2025 product revenue guidance of $194-200 million, including $12-15 million for IFC, projecting 8-11% growth from 2024.

Cerus (Nasdaq: CERS) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management team is scheduled to present at a fireside chat on Wednesday, March 5, at 11:10 a.m. EST. The presentation will be accessible through a live webcast, with a replay available for 90 days following the event.

Cerus (Nasdaq: CERS) has scheduled the release of its fourth quarter and full-year 2024 financial results for Thursday, February 20, 2025, after market close. The company will host a conference call and webcast at 4:30 P.M. ET on the same day, featuring management discussions on financial results, business overview, and outlook.

Interested participants can access the webcast and presentation slides through Cerus' Investor Relations webpage at http://ir.cerus.com. While early joining is encouraged (10 minutes prior), it's not mandatory. A replay of the event will be available on the company's website approximately three hours after the call until March 6, 2025.